Coronary/Structural Heart

BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure

November 25, 2024 09:21 AM Eastern Standard Time BURLINGTON, Mass.–(BUSINESS WIRE)–BrioHealth Solutions, Inc., a developer of world-leading technology in ventricular assist systems, announced today it has enrolled its first patients in the U.S. for the INNOVATE Trial of the BrioVAD® System. BrioHealth Solutions announced today the first patients have been enrolled […]

Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies

DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the successful closing of a $20.4 million round of financing. This funding will enable Secretome to initiate clinical trials for its lead asset, STM-01, and further advance its innovative pipeline. “We are grateful […]

Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data

November 25, 2024 03:30 AM Eastern Standard Time LONDON–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology (JACC): […]

Medtronic begins multicenter study to address health disparities in structural heart disease care

Collaboration with health technology company Tempus seeks to identify causes for undertreatment of minority patients with heart valve disease who may benefit from minimally invasive therapies Medtronic plc, a global leader in healthcare technology, today announced it began a randomized study sponsored by Tempus, a technology company leading the adoption […]

Ultromics obtains Breakthrough Device FDA clearance for its Cardiac Amyloidosis screening device through the Total Product Lifecycle Advisory Program

EchoGo® Amyloidosis is an AI-based software-only medical device, which aims to improve early detection of Cardiac Amyloidosis, an underdiagnosed cause of heart failure. EchoGo® Amyloidosis sits on Ultromics’ EchoGo® platform complementing the existing commercialized EchoGo® Heart Failure…

HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference

he studies further strengthen HeartBeam’s body of clinical evidence for its portable, cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG The first study is a pilot study demonstrating similar performance of HeartBeam’s vector-based ambulatory technology to standard 12-lead ECGs for arrhythmia detection The […]

Cardiovascular Researchers Dramatically Reduce Size and Severity of Stroke Using Antidiabetic Drug in Preclinical Models

PASADENA, Calif., Nov. 19, 2024 /PRNewswire/ — Huntington Medical Research Institutes (HMRI), a pioneer in scientific research with a track record of groundbreaking discoveries, announced promising breakthroughs in the treatment of stroke at the American Heart Association (AHA)…